Elisa Baldelli

The KRASG12C Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients

Jill Hallin, Lars D. Engstrom, Lauren Hargis et al. · Cancer Discovery · 2019 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +17

Phosphoinositide-3-Kinase Catalytic Alpha and KRAS Mutations are Important Predictors of Resistance to Therapy with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-small Cell Lung Cancer

Vienna Ludovini, Fortunato Bianconi, Lorenza Pistola et al. · Journal of Thoracic Oncology · 2011 · 179 citations · Full text

Medicine, Oncology, Pharmacology +14

Combination Therapies with CDK4/6 Inhibitors to Treat <i>KRAS-</i> Mutant Pancreatic Cancer

Craig M. Goodwin, Andrew M. Waters, Jennifer E. Klomp et al. · Cancer Research · 2022 · 160 citations · Full text

Medicine, Oncology, Pharmacology +17

Reverse Phase Protein Microarrays

Elisa Baldelli, Valerie Calvert, Alex Hodge et al. · Methods in molecular biology · 2017 · 101 citations

Life Sciences, Biology, Molecular Biology +5

The Sustained Induction of c-MYC Drives Nab-Paclitaxel Resistance in Primary Pancreatic Ductal Carcinoma Cells

Erika Parasido, George Avetian, Aisha Naeem et al. · Molecular Cancer Research · 2019 · 84 citations · Full text

Medicine, Oncology, Pharmacology +17